Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
Economic evaluation of added neoadjuvant cemiplimab to upfront wide local excision for advanced cutaneous squamous cell carcinoma of the head and neck.
Journal: JID innovations : skin science from molecules to population health
Published: September 23, 2025
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.
Journal: Journal for immunotherapy of cancer
Published: July 21, 2025
Assessing Treatment Efficacy for Dermatologic Immune-Related Adverse Events: A Systematic Review.
Journal: JID innovations : skin science from molecules to population health
Published: April 27, 2025
Assessing Treatment Response to PD-1 Inhibitors in Cutaneous Squamous Cell Carcinoma: Real-World Challenges.
Journal: Dermatology practical & conceptual
Published: April 01, 2025
5-aminolevulinic acid photodynamic therapy for the treatment of basal and squamous cell carcinoma: A systematic review.
Journal: Photodiagnosis and photodynamic therapy
Published: March 27, 2025
Efficacy following discontinuation of sonidegib 200 mg daily treatment in patients with locally advanced basal cell carcinoma: Post hoc analysis of the 42-month BOLT study.
Journal: Journal of the American Academy of Dermatology
Published: May 30, 2024
Developing expert consensus for the use of hedgehog inhibitors in basal cell nevus syndrome.
Journal: Archives of dermatological research
Published: May 22, 2024
Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies.
Journal: American journal of clinical dermatology
Published: May 12, 2024
Management of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paper based on the first Europe/USA Delphi consensus process.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: March 11, 2024
De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy.
Journal: Journal of the American Academy of Dermatology
Published: February 02, 2024
Letter to the Editor re: SGIM Telehealth Position Statement.
Journal: Journal of general internal medicine
Published: September 17, 2023
Last Updated: 09/26/2026